EVER001

DRUG2 trials

Sponsors

Everest Medicines (China) Co.,Ltd.

Conditions

Focal Segmental Glomerulosclerosis (FSGS)IgA Nephropathy (IgAN)Minimal Change Disease (MCD)Primary Membranous Nephropathy

Phase 1

Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001

CompletedNCT05800873

Everest Medicines (China) Co.,Ltd.Primary Membranous Nephropathy

Start: 2023-05-15End: 2026-07-27Updated: 2026-09-15

Phase 2

Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases

RecruitingNCT07614477

Everest Medicines (China) Co.,Ltd.Focal Segmental Glomerulosclerosis (FSGS), IgA Nephropathy (IgAN), Minimal Change Disease (MCD)

Start: 2026-05-20End: 2029-03-31Target: 45Updated: 2026-08-05

Related Papers

#130 Novel Bruton's tyrosine kinase inhibitor EVER001 in Chinese patients with primary membranous nephropathy: preliminary results from a phase 1b/2a study

Nephrology Dialysis Transplantation2025-10-01